Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Active-Controlled, Phase I Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Zamerovimab and Mazorelvimab Injection (SYN023) in Combination With Rabies Vaccine in Healthy Subjects Under 18 Years of Age

NCT07342257 is registered in ClinicalTrials.gov with Synermore Biologics (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT07342257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07342257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Active-Controlled, Phase I Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Zamerovimab and Mazorelvimab Injection (SYN023) in Combination With Rabies Vaccine in Healthy Subjects Under 18 Years of Age
Lead sponsor
Synermore Biologics (Suzhou) Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2024
Completion date
July 23, 2025
Enrollment
108 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rabies post-exposure prophylaxis